Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)
Back to Freepaper Session

Safety of prophylactic intracameral moxifloxacin during phacoemulsification

Session Details

Session Title: Cystoid Macular Oedema and Infection

Session Date/Time: Sunday 06/10/2013 | 16:30-18:00

Paper Time: 17:26

Venue: Forum (Ground Floor)

First Author: : M.Saif EGYPT

Co Author(s): :    S. Amer   A. Saif   P. Saif        

Abstract Details


to evaluate the safety of Intracameral moxifloxacin during standard coaxial phacoemulsification


Sixty patients with 60 eyes


divided into two Groups: Group, 1: Vigamox group ( 30 eyes) Group 2: Control group ( 30 eyes) Injection of 0.1cc Moxifloxacin using insulin 30G syringe in group 1were done at the end of Standard coaxial phacoemulsification with Foldable IOL


The mean age was 64.2 + 7.8 years .The preoperative VA range from HM to 6/12 which changed postoperatively as mostly improved more than 6/18 with a total lines gained up to 12 lines .The intraoperative complications, were few in which 4 eyes showed posterior capsular dehiscence, 1 eye with Positive Vitreous Pressure(3.3%)& one case of Vitreous Prolapse (3.3%). Post-operative complications was corneal edema which was slightly more in vigamox group than that occurring in the control group , corneal edema occurred in 8 cases in the vigamox group and 6 cases in the control group, 5 cases suffered from Suture-Induced Astigmatism. Unfortunately there was one case suffered from endophthalmitis ,one with Pupillary Block , one with Retained Lens Material , one case of media opacity, also one case with Shallow Anterior Chamber The average endothelial cell density in the control group was 2366.75 and changed to 2083.75.While the average endothelial cell density in the vigamox group was 2533.21 then one month postoperatively changed to 2006.29 meaning that there was a decrease of 283 in the control group compared to the 526.93 decrease in the vigamox group


Intracameral 0.1 ml of 0.5% moxifloxacin (Vigamox, Alcon) was found to be safe for the visual rehabilitation and corneal endothelium,. Use of Intracameral moxifloxacin can be a beneficial adjunct to topical dosing for surgical prophylaxis.

Financial Interest:


loading Please wait while information is loading.